Myositis kliniske forsøg i Texas
7 studier for Myositis søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients, Dallas
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
RekruttererFase 2/3
Alder 6 til 75 · Alle køn · Opdateret 17. sep. 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Texas - Houston, Houston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07103746A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Integrative Rheumatology of South Texas, Edinburg
- Arthritis & Rheumatology Research Institute, PLLC, Frisco
- Integrative Rheumatology of South Texas, Harlingen
- og 3 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT05895786Descartes-08 in Autoantibody Myositis
- National Neuromuscular Research Institute, Austin
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT07391605A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Dallas
- Nkarta Investigational Site, Houston
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 7. aug. 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Arlington, Arlington
- Artiva Investigational Site Bellaire, Bellaire
- Artiva Investigational Site Irving, Irving
- og 4 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06991114Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
- Austin Neuromuscular Center, Austin
- Austin Neuromuscular Center, Austin
RekruttererTidlig fase 1
Alder 45 til 75 · Alle køn · Opdateret 16. jan. 2026 · NCT06479863Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.